Matthew Kaplan

Stock Analyst at Ladenburg Thalmann

(2.82)
# 1,648
Out of 5,127 analysts
26
Total ratings
62.5%
Success rate
19%
Average return

Stocks Rated by Matthew Kaplan

United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319$344
Current: $490.83
Upside: -29.91%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48$54
Current: $23.47
Upside: +127.95%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39$40
Current: $30.50
Upside: +31.15%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15$30
Current: $31.76
Upside: -5.54%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5$8.5
Current: $7.00
Upside: +21.43%
Avadel Pharmaceuticals
May 2, 2023
Maintains: Buy
Price Target: $15$16
Current: $21.48
Upside: -25.51%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.19
Upside: +48,916.02%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340$460
Current: $0.95
Upside: +48,097.82%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $7.53
Upside: +577.29%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $35.57
Upside: -55.02%
Initiates: Buy
Price Target: $45
Current: $5.61
Upside: +702.14%